Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0113-5840 · 1 trial · 2 indications
Measured as number of events.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 NNC0113-5840 | EXPERIMENTAL | Participants will be randomized to receive NNC0113-5840 single dose level 1 subcutaneously. |
| Cohort 2 NNC0113-5840 | EXPERIMENTAL | Participants will be randomized to receive NNC0113-5840 single dose level 2 subcutaneously. |
| Cohort 3 NNC0113-5840 | EXPERIMENTAL | Participants will be randomized to receive NNC0113-5840 single dose level 3 subcutaneously. |
| Cohort 4 NNC0113-5840 | EXPERIMENTAL | Participants will be randomized to receive NNC0113-5840 single dose level 4 subcutaneously. |
| Cohort 5 NNC0113-5840 | EXPERIMENTAL | Participants will be randomized to receive NNC0113-5840 single dose level 5 subcutaneously. |
| Cohort 6 NNC0113-5840 | EXPERIMENTAL | Participants will be randomized to receive NNC0113-5840 single dose level 6 subcutaneously. |
| Placebo matching NNC0113-5840 | PLACEBO_COMPARATOR | Participants will receive placebo matched to NNC0113-5840 subcutaneously. |
| Name | Type | Description |
|---|---|---|
| NNC0113-5840 | DRUG | NNC0113-5840 will be administered subcutaneously using needle and syringe in a lifted fold of the abdominal skin. |
| Placebo | DRUG | Placebo matched to NNC0113-5840 will be administered subcutaneously using needle and syringe in a lifted fold of the abdominal skin. |
Inclusion Criteria: 1. Male or female 2. Age 18-55 years (both inclusive) at the time of signing the informed consent. 3. Body mass index (BMI) between 25.0 and 34.9 kilogram per meter square (kg/m2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the ...
Top 20 of 32 competitors
NNC0113-5840 is an investigational small molecule being developed for the treatment of obesity and overweight. It is currently in Phase 1 clinical development, with a study recruiting participants in the United States who are 18 years and older.
NNC0113-5840 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting clinical trials to evaluate the drug's effects in people with overweight or obesity.
NNC0113-5840 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety and how it works in the body.
NNC0113-5840 is being studied in a Phase 1 clinical trial with the identifier NCT07566390. This randomized, double-blind, placebo-controlled study is investigating how the new medicine works in people with overweight or obesity, with an enrollment of 48 participants in the United States.
NNC0113-5840 is the specific name of this investigational drug candidate. No alternative names have been reported for this compound in the available clinical trial information.